Searchable abstracts of presentations at key conferences in endocrinology

ea0052p36 | (1) | UKINETS2017

Phase 1/2 open-label trial to assess the safety and preliminary efficacy of 177Lu-OPS201 as peptide receptor radionuclide therapy in patients with somatostatin receptor-positive, progressive neuroendocrine tumours

Nicolas Guillaume , Baum Richard , Herrmann Ken , Lassmann Michael , Hicks Rodney , Haug Alexander , Navalkissoor Shaunak , Oberwittler Heike , Wang Tiffany , Wild Damian

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

ea0047oc14 | Spotlight on Neuroendocrine tumours | Theranostics2016

68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT

Lassmann Michael , Werner Rudolf A. , Weich Alexander , Wester Hans-Juergen , Scheurlen Michael , Higuchi Takahiro , Samnick Samuel , Bluemel Christina , Rudelius Martina , Buck Andreas K. , Lapa Constantin , Herrmann Ken

Introduction: Diagnostic imaging of neuroendocrine tumors (NETs) is the domain of somatostatin receptor (SSTR) agonists as well as FDG PET/CT in dedifferentiated tumors. SSTR also serves as target for receptor directed peptide therapy. More recently, specific ligands targeting the chemokine receptor 4 (CXCR4) were introduced potentially offering an additional theranostic option in NETs. Here we evaluated the CXCR4 expression using 68Ga-Pentixafor PET/CT in NET patie...

ea0037oc1.3 | Adrenal 1 | ECE2015

[123/131I] azetidinylamide a novel radiotracer for diagnosis and treatment of adrenocortical tumours -- from bench to bedside

Hahner Stefanie , Heinze Britta , Herrmann Ken , Buck Andreas K , Blumel Christina , Hanscheid Heribert , Brumberg Joachim , Michelmann David , Nannen Lukas , Ries Martin , Fassnacht Martin , Allolio Bruno , Schirbel Andreas

Background: We have recently introduced [123/131I]iodometomidate (IMTO) which selectively binds to the adrenocortical enzymes aldosterone synthase and 11ß-hydroxylase as SPECT tracer. IMTO has been proven to be useful for molecular adrenal imaging and radiotherapy in adrenal cancer (ACC). As IMTO is rapidly inactivated by endogenous esterases which may impair target tissue to background activity and therapeutic efficacy, >50 new IMTO derivatives have been d...

ea0089t2 | Trials In Progress | NANETS2022

COMPOSE: Pivotal Phase III Trial for Well-Differentiated Aggressive Grade 2/3 Gastroenteropancreatic Neuroendocrine Tumors Comparing 177Lu-edotreotide with Best Standard of Care

R Halfdanarson Thorvardur , M Halperin Daniel , Reidy-Lagunes Diane , Kong Grace , Capdevila Jaume , Mailman Josh , Herrmann Ken , Srirajaskanthan Rajaventhan , Leyden Simone , Thevenet Thomas , Harris Philip

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which frequently develop metastatic disease, represent an estimated 70% of NETs. There are limited treatment options with current standard therapies for well-differentiated aggressive grade 2 and grade 3 (Ki-67 index 15−55%) GEP-NETs; however, these may include somatostatin analogues; peptide receptor radionuclide therapy (PRRT); molecular targeted therapies (everolimus or sunitinib); chemotherapy; and ...